Catalent CEO to remain in charge of contract drugmaker

Catalent’s Maselli to continue as CEO post Novo Holdings deal close
Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to an open letter to customers. In the letter addressing customers, Maselli said,
Catalent tries to reassure customers about its deal with Novo Holdings
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 billion deal will not raise competitive concerns.
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk.
Novo Holdings' $16.5B Catalent buyout in crosshairs as consumer groups ask FTC to block the deal
Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. | A dozen consumer groups and trade unions penned a letter to Lina Khan,
Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers:
Consumer groups ask FTC to block Novo Holdings-Catalent deal
U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk , from acquiring contract drug manufacturer Catalent ,
Warren calls on FTC to scrutinize Novo Holdings' $16.5B Catalent buyout
As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S. Federal Trade Commission,
Catalent Issues Open Letter To Customers; To Operate As Full-service CDMO Under Novo
Catalent, Inc. (CTLT) said, following the closing of transaction, as a private company under Novo Holdings' ownership, Catalent will ...
STAT4d
Consumer and labor groups urge FTC to block Catalent sale to Novo Holdings
The coalition said in a letter sent to the FTC Thursday that the deal could reduce access to GLP-1s, and harm competition in ...
BioSpace11d
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...
NJBIZ6d
Catalent to sell Somerset HQ (updated)
The site also serves as an oral solids development and small-scale manufacturing facility for the pharmaceutical company, ...
devdiscourse4d
FTC Urged to Block Novo Holdings' Catalent Acquisition Amid Competition Concerns
U.S. consumer groups and labor unions are urging the FTC to block Novo Holdings' acquisition of Catalent. They argue it could ...